MapLight Therapeutics (MPLT) Income towards Parent Company (2024 - 2026)
MapLight Therapeutics (MPLT) posted Income towards Parent Company of -$81.2 million for Q4 2025, down 138.36% sequentially from -$34.1 million in Q3 2025, and down 276.34% YoY from $46.1 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Income towards Parent Company (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Income towards Parent Company for 2 years, with the latest figure at -$81.2 million in Q4 2025.
- Quarterly Income towards Parent Company fell 276.34% year-over-year to -$81.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$157.0 million (changed N/A YoY) and the FY2025 annual result came in at -$176.2 million, down 93.77% from the prior year.
- Income towards Parent Company retreated to -$81.2 million in Q4 2025 per MPLT's latest filing, from -$34.1 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$20.1 million in Q3 2024 and troughed at -$81.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | MapLight Therapeutics | 630.59 Mn | 630.59 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -61.20 Mn |
| Dec 31, 2025 | -80.91 Mn |
| Sep 30, 2025 | -29.95 Mn |
| Jun 30, 2025 | -29.98 Mn |
| Dec 31, 2024 | -21.88 Mn |
| Sep 30, 2024 | -19.81 Mn |